Literature DB >> 9598023

Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment.

H Yamanaka1, R Togashi, M Hakoda, C Terai, S Kashiwazaki, T Dan, N Kamatani.   

Abstract

To find an optimal range of urate concentrations wherein the risk of attacks during the initial 6 months of treatment is minimized, data from 350 gouty patients treated with anti-hyperuricemic drugs were retrospectively analyzed. We determined the optimal range of urate concentrations to be 4.6-6.6 mg/dl. If urate concentrations were within this range, the risk ratio of an attack as opposed to outside of the range was 0.705 (95% confidence interval, 0.629-0.791). The increase (or decrease) in urate concentration in one month associated with minimal risk of gouty attacks was also determined. The lowest risk ratio of attack (0.451) occurred at a range of -0.1 to 0.6 mg/dl/month increase in urate concentrations (95% confidence interval, 0.310-0.655). In conclusion, we propose that urate concentrations during the initial 6 months of anti-hyperuricemic therapy should be maintained within a range of 4.6-6.6 mg/dl, and reduction in the urate concentrations during treatment should be as slow as possible.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9598023     DOI: 10.1007/978-1-4615-5381-6_3

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  17 in total

Review 1.  Difficult-to-treat gouty arthritis: a disease warranting better management.

Authors:  Naomi Schlesinger
Journal:  Drugs       Date:  2011-07-30       Impact factor: 9.546

2.  [Diagnosis and management of gout in Austria. Survey of current practice considering the EULAR recommendations].

Authors:  J Sautner
Journal:  Z Rheumatol       Date:  2014-11       Impact factor: 1.372

Review 3.  How neutrophil extracellular traps orchestrate the local immune response in gout.

Authors:  Christian Maueröder; Deborah Kienhöfer; Jonas Hahn; Christine Schauer; Bernhard Manger; Georg Schett; Martin Herrmann; Markus H Hoffmann
Journal:  J Mol Med (Berl)       Date:  2015-05-24       Impact factor: 4.599

4.  Questionnaire survey evaluating disease-related knowledge for 149 primary gout patients and 184 doctors in South China.

Authors:  Qian-Hua Li; Lie Dai; Zhao-Xia Li; Hai-Jun Liu; Chan-Juan Zou; Xia Ou-Yang; Meng Lu; Ting Li; Yan-Hua Li; Yin-Qian Mo; H Ralph Schumacher
Journal:  Clin Rheumatol       Date:  2013-07-16       Impact factor: 2.980

Review 5.  Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal.

Authors:  Matt Stevenson; Abdullah Pandor
Journal:  Pharmacoeconomics       Date:  2011-02       Impact factor: 4.981

Review 6.  New developments in clinically relevant mechanisms and treatment of hyperuricemia.

Authors:  Susan J Lee; Robert A Terkeltaub
Journal:  Curr Rheumatol Rep       Date:  2006-06       Impact factor: 4.592

7.  Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.

Authors:  Mattheus K Reinders; Eric N van Roon; Pieternella M Houtman; Jacobus R B J Brouwers; Tim L Th A Jansen
Journal:  Clin Rheumatol       Date:  2007-02-17       Impact factor: 2.980

8.  Effects of the Dietary Approaches to Stop Hypertension (DASH) Diet and Sodium Intake on Serum Uric Acid.

Authors:  Stephen P Juraschek; Allan C Gelber; Hyon K Choi; Lawrence J Appel; Edgar R Miller
Journal:  Arthritis Rheumatol       Date:  2016-12       Impact factor: 10.995

Review 9.  Management of hyperuricemia in gout: focus on febuxostat.

Authors:  Mattheus K Reinders; Tim L Th A Jansen
Journal:  Clin Interv Aging       Date:  2010-02-02       Impact factor: 4.458

10.  New advances in the treatment of gout: review of pegloticase.

Authors:  Mattheus K Reinders; Tim L Th A Jansen
Journal:  Ther Clin Risk Manag       Date:  2010-10-27       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.